Gene alterations, clinical informations and survival data of gliomas with/without corpus callosum involvement

The raw dataset of this study contained the gene alterations, clinical informations and survival data of glioma patients. Gene alterations data were obtained by Next-generation DNA sequencing of glioma samples of patients. Clinical informations were obtained from Electronic medical records and follow-up. The survival data were obtained by follow-up of patients. In order to explore gene alterations and their correlation with the survival of glioblastoma (GBM) of corpus callosum (CC) involvement (ccGBM), this dataset was analyzed in detail. A total of 30 ccGBM and 88 non-ccGBM were finally included. The ccGBM had higher incidence of PDGFRA (33.3% versus 9.1%, P=0.004) alterations than non-ccGBM. PDGFRA amplification (PDGFRAamp, 33.3% versus 9.1%, P=0.004) and missense mutation (PDGFRAmut, 20.0% versus 3.4%, P=0.011) both had higher incidence in ccGBM than in non-ccGBM. PDGFRA alteration was significantly associated with the occurrence of ccGBM (OR=4.91 [95%CI: 1.55-15.52], P=0.007). The ccGBM of PDGFRAamp achieved shorter median PFS (8.6 versus 13.5 months, P=0.025) and OS (12.4 versus 17.9 months, P=0.022) than non-ccGBM of PDGFRAnon-amp. The ccGBM of PDGFRAamp combined with PDGFRAmut (PDGFRAamp-mut) had shorter median PFS (7.6 versus 8.9 months, P=0.022) and OS (9.6 versus 17.8 months, P=0.006) than non-ccGBM of PDGFRA wild type and non-amplification (PDGFRA-w, non-amp). Compared to ccGBM of PDGFRA-w, non-amp, the ccGBM of PDGFRAamp and PDGFRAamp-mut both had shorter median PFS and OS (P<0.05). Hazard ratios (HRs) of PDGFRAamp for PFS and OS of ccGBM were 3.08 (95%CI: 1.02-9.35, P=0.047) and 5.07 (95%CI: 1.52-16.89, P=0.008) respectively, HRs of PDGFRAamp-mut for PFS and OS were 13.16 (95%CI: 3.19-54.40, P<0.001) and 16.36 (95%CI: 2.66-100.70, P=0.003) respectively. The PDGFRA alterations is significantly associated with the occurrence and poor prognosis of ccGBM.